Week 11 - Stereotactic Flashcards

1
Q

stereotactic RT

A
  • highly precise treatment
  • small targets
  • high doses
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

treatment principles

A
  • use of multiple non-coplanar beams or arcs
  • achieves a steep dose gradient
    • minimal dose to critical structures and surrounding healthy tissue
  • achieves conformity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

SRS

A

radiosurgery
- single, high dose of radiation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

SRT

A

stereotactic radiotherapy
- treatment is delivered in more than one fraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

indications for SRS/SRT

A
  • small tumour size
  • tumour location
  • pathology of tumour
  • the patient
  • tumour recurrence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

advantages of stereo over VMAT

A
  • minimal damage to surrounding tissue
  • treat to higher doses
  • treatment can be given multiple times
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

cranial tumour sites

A
  • acoustic neuroma
  • meningioma
  • cranial metastases
  • GBM (glioblastoma multiforme)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

acoustic neuroma + presentation + treatment

A
  • benign tumour of the 8th cranial nerve

presentation: hearing loss, tinnitus, balance disturbances

treatment: SRS utilised when surgery risks damage to facial nerves and hearing
- SRS 12.5Gy in 1#

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

meningioma + treatment (SRS and SRT)

A
  • usually benign tumour arising from meningeal tissue

stereotactic for inoperable or small tumours
- SRS 18-20Gy
- SRT 50-60Gy @ 1.8-2Gy per #

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

brain metastases + treatment dose

A
  • metastases in the brain arise from a variety of primary sites
  • patients can present with 1 or many mets

stereotactic dose of 16-20Gy in 1# per met

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

GBM + symptoms + treatment

A
  • highly malignant and fast growing - average survival time 12 months

symptoms: headaches, nausea, seizures, memory loss, changes in speech or personality and walking difficulties

stereotactic used at time of recurrence
- SRS 6-16Gy in 1#

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

MRI in SRS/SRT

A
  • essential for all patients
  • provide excellent definition of tumour volume and critical structures
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

CT slice thickness

A

1mm slices for SRT/SRS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

image fusion

A
  • CT and MRI images are fused together
  • CT is always the primary image
  • fusions are automatic, but must be checked
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

dose prescription and aims for SRS/SRT

A
  • stereotactic plans are usually prescribed so that the 80% isodose line covers the PTV
  • aiming for 99% of the PTV to be covered with the prescribed dose
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

imaging tolerance

A

> 3Gy/# tol is <0.5mm
<3Gy/# tol is <0.9mm
VMAT brain tol is 3mm

17
Q

acute side effects

A

headaches, nausea, vomitting, visual disturbances, swelling (usually managed with steroids)

18
Q

delayed side effects

A

facial weakness, numbness, hearing loss